IJE Advance Access originally published online on September 12, 2005
International Journal of Epidemiology 2005 34(5):979-986; doi:10.1093/ije/dyi164
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2005; all rights reserved.
Cohort Profiles |
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Study Group*Correspondence to: François Dabis, INSERM U.593, ISPED, Université Victor Segalen, 146 Rue Léo Saignat, 33076 Bordeaux Cedex, France. E-mail: francois.dabis@isped.u-bordeaux2.fr
| The first 150 words of the full text of this article appear below. |
 |
Dedication |
|---|
This manuscript is dedicated to the memory of Dr Nicholas Hone, pioneer of HIV care in Botswana and member of the ART-LINC collaboration, who died prematurely at the beginning of the project.
|
How did the study come about? |
|---|
Highly active antiretroviral therapy (HAART), a combination of at least three drugs, has substantially improved the prognosis of HIV-infected patients in industrialized countries.1–3 In resource-poor settings in Africa, Asia, and South America, where 90% of people with HIV/AIDS live, access to HAART continues to be limited. It is estimated that one million HIV-1 infected individuals presently receive HAART in low-income and middle-income countries, which represents only 15% of the 6.5 million people urgently in need of such treatment in these settings.4 International and bilateral initiatives, including WHO's ‘3 by 5’ target (3 million patients treated by 2005), the Global Fund to fight AIDS, Tuberculosis and Malaria, and the United States President's Emergency Plan for AIDS Relief (PEPFAR), aim
|
Who set ART-LINC up and how is it funded? |
|---|
|
What does ART-LINC cover and who is included in the sample? |
|---|
|
Characteristics of treatment programmes |
|---|
|
Patient characteristics |
|---|
|
Treatment regimens |
|---|
|
How often are participants followed-up and what is measured? |
|---|
|
What is attrition like? |
|---|
|
What has ART-LINC found? |
|---|
|
Strengths and weaknesses of the ART-LINC Collaboration |
|---|
|
Can I get hold of the data? Where can I find out more? |
|---|
|
Appendix |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The eligibility for ART in lower income countries Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies Sex. Transm. Inf., August 1, 2008; 84(Suppl_1): i31 - i36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Arrive, D. J Kyabayinze, B. Marquis, N. Tumwesigye, M.-P. Kieffer, A. Azondekon, L. Wemin, P. Fassinou, M.-L. Newell, V. Leroy, et al. Cohort Profile: The Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration Int. J. Epidemiol., June 1, 2008; 37(3): 474 - 480. [Full Text] [PDF]
|
|
|
|
|
|
C. C McGowan, P. Cahn, E. Gotuzzo, D. Padgett, J. W Pape, M. Wolff, M. Schechter, and D. R Masys Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme Int. J. Epidemiol., October 1, 2007; 36(5): 969 - 976. [Full Text] [PDF]
|
|
|
|
|
|
M. May and M. Egger Commentary: State of the ART modelling for HIV-infected children? Int. J. Epidemiol., June 1, 2007; 36(3): 687 - 689. [Full Text] [PDF]
|
|